Please login to the form below

Not currently logged in
Email:
Password:

Partner for Sanofi on pneumonia KB001

KaloBios has announced an agreement with Sanofi Pasteur for the development of KB001 for Pseudomonas aeruginosa (Pa) infections

KaloBios Pharmaceuticals has announced an agreement with Sanofi Pasteur for the development and commercialisation of KB001 for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections.

Sanofi Pasteur (the vaccines division of the sanofi-aventis Group), will be responsible for the development and commercialisation of KB001, an investigational new biologic, and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

KaloBios will focus on developing and commercialising KB001 for use in treating patients with cystic fibrosis and bronchiectasis, an obstructive lung disease aggravated by bacterial infections.

Under the terms of the agreement, KaloBios will receive an upfront payment of $35m from Sanofi Pasteur, plus development, regulatory and commercial milestones for a potential further $255m, as well as royalties on eventual product sales. Sanofi Pasteur also has the option to acquire commercial rights to KaloBios' indications for KB001 outside the US and co-promotion rights in the US.

"Hospital-based pneumonias, especially those associated with mechanically ventilated patients in the ICU, are a life-threatening complication that can significantly increase mortality and morbidity as well as add tens of thousands of dollars to the cost of a hospital stay," said Dr Tillman Pearce, chief medical officer of KaloBios.

"KB001's novel mechanism of action against Pa provides a unique means of fighting these infections, which are often resistant to antibiotic therapies. We also think this novel mechanism could have a significant impact on Pseudomonas aeruginosa infections in cystic fibrosis patients as well."

11th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...